Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Columnists Discuss HIV Statistics, National Testing Day
"It"s getting harder to convince people of the urgency, that knowing your HIV status is better than not knowing, that this is still a serious problem," columnist Wendi Thomas writes in the Memphis Commercial Appeal. She writes that some people "assume being HIV positive is no big deal" because former National Basketball Association player Earvin "Magic" Johnson has lived with HIV since 1991 and appears to be healthy. "But if you are HIV positive and delay finding out, the virus could progress" to a point where it becomes "much more difficult to treat," Thomas adds (Thomas, Memphis Commercial Appeal, 6/25). Philadelphia Inquirer columnist George Curry today discussed HIV statistics and findings from a recent Kaiser Family Foundation survey that looked at U.S. residents" views on HIV/AIDS. He said, "It"s time to refocus our attention on HIV and AIDS. And a good way to do that is by getting tested tomorrow" on National HIV Testing Day (Curry, Philadelphia Inquirer, 6/26).

What Is Ovulation? What Is The Ovulation Calendar?
Ovulation is one part of the female menstrual cycle whereby a mature ovarian follicle (part of the ovary) discharges an egg (also known as an ovum, oocyte, or female gamete). It is during this process that the egg travels down the fallopian tube where it may be met by a sperm and become fertilized.
News of the day
North Carolina State University And The University Of Strasbourg Agree To Collaborate On A Training Program
Strasbourg University and North Carolina State University, both leading academic institutions in the field of bioproduction, have entered into an agreement to collaborate on a unique set of training capabilities for industry. The Alsace Biovalley cluster has played and will continue to play a key role in the program by bringing together industry players in support of the project, ensuring that training programs meet industry needs, structuring the financial engineering required and securing funding for the infrastructures.
Oncology

Diamyd(R) Phase III Study Approved For Younger Patients In The US

Diamyd Medical reported that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company"s Phase III study with the diabetes vaccine Diamyd(R). Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients. The objective of the studies is to evaluate the ability of the Diamyd(R) vaccine to halt or delay the autoimmune attack on the body"s insulin-producing cells, thereby preserving the body"s own ability to produce insulin in children and adolescents with recent-onset type 1 diabetes. The European study, which is being conducted in nine countries, is approved for patients between 10 and 20 years of age, whilst the US study so far has been approved only for patients 16 to 20 years, an age group with few recent-onset type 1 diabetes patients. The company is, with the new approval, allowed to begin enrollment of children from 10 years of age in the US phase III study. "This is a big step forward giving us the opportunity to accelerate patient recruitment in the US," says Elisabeth Lindner, President and CEO of Diamyd Medical. "We are pleased that the approval comes now in connection with the world"s largest diabetes conference, the ADA"s 69th Scientific Sessions, which is currently ongoing in New Orleans." The company will now, in pace with Institutional Review Board (IRB) approvals in USA, increase the number of American pediatric clinics in the study. The application for market approval is, as before, planned for spring 2011. Diamyd Medical is represented at booth #2431 at the ADA"s 69th Scientific Sessions in New Orleans, USA. About Diamyd Medical Diamyd Medical is a Swedish biopharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company"s most advanced project is the GAD-based drug Diamyd(R) for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has started clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson"s disease. The company has currently three clinical-phase products. Diamyd Medical has offices in Sweden and in the US. Shares are listed on the Nasdaq OMX Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements Diamyd Medical AB (publ)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009